Bin Huang
Director/Board Member chez 3SBIO INC.
Fortune : 25 M $ au 31/03/2024
Profil
Bin Huang is currently a Non-Executive Director at 3SBio, Inc. and a Director at Collected Mind Ltd.
He is also the General Manager & Director at Taizhou Huan Sheng Investment Management Co., Ltd.
Additionally, Mr. Huang holds the position of Director & Vice President at Shenyang Sunshine Pharmaceuticals Co., Ltd.
In the past, he served as the Vice President-Business Development at Chemokine Therapeutics Corp.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
3SBIO, INC.
1,32% | 30/06/2023 | 32 197 350 ( 1,32% ) | 25 M $ | 31/03/2024 |
Postes actifs de Bin Huang
| Sociétés | Poste | Début |
|---|---|---|
| 3SBIO INC. | Director/Board Member | 01/01/2006 |
Collected Mind Ltd.
 Collected Mind Ltd. Financial ConglomeratesFinance Part of 3SBio, Inc., Collected Mind Ltd. functions as an investment holding There is no available country named vg company. | Director/Board Member | 01/08/2006 |
| Taizhou Huan Sheng Investment Management Co., Ltd. | Chief Executive Officer | 01/11/2010 |
Shenyang Sunshine Pharmaceuticals Co., Ltd.
 Shenyang Sunshine Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Shenyang Sunshine Pharmaceutical Co., Ltd. engages in the development and production of biological products. It offers recombinant human erythropoietin, interferon alfa 2b, interleukin 2, and thrombopoietin injections. Its business activities include research and development, and manufacture of biochemical reagents, and pharmaceutical project investment advisory services. The company was founded on January 3, 1993 and is headquartered in Shenyang, China. | Director/Board Member | 01/01/1993 |
Anciens postes connus de Bin Huang
| Sociétés | Poste | Fin |
|---|---|---|
Chemokine Therapeutics Corp.
 Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| 3SBIO INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Chemokine Therapeutics Corp.
Chemokine Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Chemokine Therapeutics Corp. is a biotechnology company, developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases. The company's product candidates in clinical trials include CTCE-0214, for enhancing the immune system; and CTCE-9908, to prevent the spread of cancer and its continued growth. Chemokine Therapeutics was founded on July 15, 1998 and is headquartered in Vancouver, Canada. | Health Technology |
Collected Mind Ltd.
Collected Mind Ltd. Financial ConglomeratesFinance Part of 3SBio, Inc., Collected Mind Ltd. functions as an investment holding There is no available country named vg company. | Finance |
Shenyang Sunshine Pharmaceuticals Co., Ltd.
Shenyang Sunshine Pharmaceuticals Co., Ltd. BiotechnologyHealth Technology Shenyang Sunshine Pharmaceutical Co., Ltd. engages in the development and production of biological products. It offers recombinant human erythropoietin, interferon alfa 2b, interleukin 2, and thrombopoietin injections. Its business activities include research and development, and manufacture of biochemical reagents, and pharmaceutical project investment advisory services. The company was founded on January 3, 1993 and is headquartered in Shenyang, China. | Health Technology |
